Congratulations to Dr. Malani!

Congratulations to Dr. Malani!Our team here at AIMS Institute would like to offer our congratulations to Dr. Malani for receiving her American Board of Naturopathic Oncology certification! This achievement is held by only the most elite practitioners in the field, and we are proud to celebrate Dr. Malani for reaching this huge milestone and career achievement.

Dr. Malani was the inaugural resident here at AIMS Institute, and as a certified naturopathic oncologist, she is qualified to use natural healing methods to aid in cancer care and treatment to deliver the best possible outcomes for her patients. By completing her ABNO certification, she has demonstrated outstanding competence in both naturopathic and conventional oncology, meeting the highest standard in the profession.

Please join us in offering our sincerest congratulations to Dr. Malani for this outstanding achievement!

Leave a Reply

Latest Blog Posts

Proactive Breast Health: Self-Care and Self-Exam Tips for Breast Cancer Prevention

Proactive Breast Health: Self-Care and Self-Exam Tips for Breast Cancer Prevention

by Clinical Consulting Team This post was written by our guest author, Raushanah Najeeullah, ND. Breast cancer affects approximately one in eight women, making it one of the most common cancers worldwide. While genetic factors can influence breast cancer risk, lifestyle choices and early detection play an important role in prevention. Nutrient and hormone influences, and possibly estrogen metabolism, might be contributors to breast cancer development. Select use of testing and addressing results, could influence optimal breast health and may be associated with reducing breast cancer risk. The DUTCH Test (Dried Urine Test for Comprehensive Hormones) provides potential valuable insights ...

Read More
New Urine Test Reduces Unnecessary Biopsies in Prostate Cancer Detection

New Urine Test Reduces Unnecessary Biopsies in Prostate Cancer Detection

Author: Raushanah Najeeullah, ND A new urine test, MyProstateScore 2.0 (MPS2), offers better accuracy for detecting high-grade prostate cancer compared to current methods. In a recent study involving over 1,500 men, MPS2 reduced unnecessary biopsies by up to 51% while still identifying significant cancers with high sensitivity. This test improves on the PSA test by specifically targeting 17 genes linked to high grade aggressive prostate cancer, making it a promising non-invasive tool for reducing the risks and discomfort associated with prostate cancer screening. Source: Tosoian JJ, Zhang Y, Xiao L, et al. Development and Validation of an 18-Gene Urine Test ...

Read More
Brain cancer update

Brain cancer update

July 12, 2024 Leanna Standish IV CURCUMIN AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma.  Curcumin is the molecule present in turmeric root that has anticancer activity.  Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells.  We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth.  Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY.  Last year we presented ...

Read More
Call Us Text Us
Skip to content